spacer
home > ict > spring 2020 > the future awaits us
PUBLICATIONS
International Clinical Trials

The Future Awaits Us






EPC: In Medical Writing – A Bold New Path: The Future Awaits Us, Lisa A Cloutier at Janssen Research & Development discusses outsourcing trends in medical writing. What do you think the future will hold for medical writing services?

Barry Drees: I have been in medical writing for over 30 years, and it seems that every five years or so, the outsourcing trend pendulum swings back and forth between ‘everything should be done in-house’ and ‘virtual company: outsource everything’. I believe that the ideal solution is somewhere in the middle, where a company maintains a core of medical writing experience but uses outside contractors in times of peak demand (such as large submissions) or for specialist expertise. So, I see a very secure future for contract medical writers.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author

Barry Drees received his PhD in Molecular Genetics at the University of California, US. Following his postdoctoral work as a fellow of the National Institute of Health, he worked as a Medical Writer at Hoechst/Aventis for 12 years. Barry is a frequent speaker on medical writing, statistics, and other scientific communication topics for a number of associations and companies in the pharma industry. He is a past President of the European Medical Writers Association (EMWA) and is a former Editorin- Chief of the EMWA journal. He is currently a Co-Founder and Senior Partner of Trilogy Writing & Consulting, continuing to personally lead submission teams and provide training for the industry around the world.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Gelomics Partners With Rousselot Biomedical to Create the World’s First, Ready-to-Use 3D Cell Culture Kits Based on X-PURE® GelMA

Irving, United States, 16th November 2022 / Sciad Newswire / Darling Ingredients’ Health Brand, Rousselot, the global leader in collagen-based solutions, and Gelomics, the world-leading provider of fully integrated 3D cell, organoid and tissue culture technologies, have entered into a cobranding partnership. Rousselot Biomedical will supply Gelomics with its X-Pure GelMA (gelatin methacryloyl), a photo cross-linkable extracellular matrix, for use in Gelomics’ LunaGel™ 3D Tissue Culture System.
More info >>

White Papers

Role of Comparators in Clinical Trial Supply

Clinical Services International

CSI analyses the role of comparators in different trial designs and offers expert advice on robust methodology for choosing the most appropriate comparators. Case studies provide real insight on how to choose comparators for rare diseases and oncology studies.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement